Global Live Attenuated Influenza Vaccine (LAIV) Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030

Page: 118

Published Date: 08 Jan 2024

Category: Pharma & Healthcare

PDF Download

Get FREE Sample

Customize Request

Description
Table of Contents
Table of Figures
Research Methodology
Companies Mentioned
Related Reports
Product Tags

Description

According to our (Global Info Research) latest study, the global Live Attenuated Influenza Vaccine (LAIV) market size was valued at USD 7964.6 million in 2023 and is forecast to a readjusted size of USD 12000 million by 2030 with a CAGR of 6.0% during review period.

A Live Attenuated Influenza Vaccine (LAIV), also known as the "nasal spray" or "intranasal" flu vaccine, is a type of influenza vaccine that is designed to provide immunity against the influenza virus. Unlike traditional injectable influenza vaccines, which contain inactivated (killed) virus particles, LAIV contains a weakened, live influenza virus. This live virus is attenuated, meaning it has been modified to reduce its virulence (ability to cause disease) while still retaining the capacity to stimulate an immune response.

Evolving Vaccine Formulations: The LAIV formulation changes annually to match the prevalent influenza virus strains. Researchers continually monitor and adapt the vaccine to ensure it provides protection against the most relevant strains. This requires ongoing research and development efforts.

Preference for Non-Invasive Vaccination: The nasal spray administration method of LAIV is preferred by some individuals, particularly children and those who are averse to needles. This preference has driven demand for LAIV, especially among pediatric populations.

Efficacy and Effectiveness Research: Ongoing research is aimed at improving the effectiveness and stability of LAIV. Ensuring the vaccine's effectiveness is crucial in maintaining public confidence and its role in influenza prevention.

Enhanced Cold Chain Management: As LAIV is a live vaccine, it requires specific storage and transport conditions to maintain its viability. Advances in cold chain management are essential to preserve the vaccine's effectiveness.

Global Variations in Approval: Approval and recommendations for LAIV can vary by country and region. Some countries may be more enthusiastic about LAIV, while others may have specific guidelines and restrictions regarding its use.

The Global Info Research report includes an overview of the development of the Live Attenuated Influenza Vaccine (LAIV) industry chain, the market status of Hospital (Trivalent Flu Vaccine, Quadrivalent Flu Vaccine), Clinic (Trivalent Flu Vaccine, Quadrivalent Flu Vaccine), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Live Attenuated Influenza Vaccine (LAIV).

Regionally, the report analyzes the Live Attenuated Influenza Vaccine (LAIV) markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Live Attenuated Influenza Vaccine (LAIV) market, with robust domestic demand, supportive policies, and a strong manufacturing base.

Key Features:
The report presents comprehensive understanding of the Live Attenuated Influenza Vaccine (LAIV) market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Live Attenuated Influenza Vaccine (LAIV) industry.

The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the sales quantity (K Units), revenue generated, and market share of different by Type (e.g., Trivalent Flu Vaccine, Quadrivalent Flu Vaccine).

Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Live Attenuated Influenza Vaccine (LAIV) market.

Regional Analysis: The report involves examining the Live Attenuated Influenza Vaccine (LAIV) market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.

Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Live Attenuated Influenza Vaccine (LAIV) market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.

The report also involves a more granular approach to Live Attenuated Influenza Vaccine (LAIV):
Company Analysis: Report covers individual Live Attenuated Influenza Vaccine (LAIV) manufacturers, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.

Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Live Attenuated Influenza Vaccine (LAIV) This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Hospital, Clinic).

Technology Analysis: Report covers specific technologies relevant to Live Attenuated Influenza Vaccine (LAIV). It assesses the current state, advancements, and potential future developments in Live Attenuated Influenza Vaccine (LAIV) areas.

Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Live Attenuated Influenza Vaccine (LAIV) market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.

Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.

Market Segmentation
Live Attenuated Influenza Vaccine (LAIV) market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.

Market segment by Type
Trivalent Flu Vaccine
Quadrivalent Flu Vaccine

Market segment by Application
Hospital
Clinic
Public Health Agency
Other

Major players covered
Sanofi Pasteur
AstraZeneca
CSL
Abbott
GlaxoSmithKline
Serum Institute
Fluenz Tetra
Cytiva
BioDiem
FluMist
GSK
ChangChun High & New Technology
BCHT Biotechnology

Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Live Attenuated Influenza Vaccine (LAIV) product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Live Attenuated Influenza Vaccine (LAIV), with price, sales, revenue and global market share of Live Attenuated Influenza Vaccine (LAIV) from 2019 to 2024.
Chapter 3, the Live Attenuated Influenza Vaccine (LAIV) competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Live Attenuated Influenza Vaccine (LAIV) breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2019 to 2030.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2019 to 2030.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2023.and Live Attenuated Influenza Vaccine (LAIV) market forecast, by regions, type and application, with sales and revenue, from 2025 to 2030.
Chapter 12, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Live Attenuated Influenza Vaccine (LAIV).
Chapter 14 and 15, to describe Live Attenuated Influenza Vaccine (LAIV) sales channel, distributors, customers, research findings and conclusion.

Table of Contents

1 Market Overview
    1.1 Product Overview and Scope of Live Attenuated Influenza Vaccine (LAIV)
    1.2 Market Estimation Caveats and Base Year
    1.3 Market Analysis by Type
        1.3.1 Overview: Global Live Attenuated Influenza Vaccine (LAIV) Consumption Value by Type: 2019 Versus 2023 Versus 2030
        1.3.2 Trivalent Flu Vaccine
        1.3.3 Quadrivalent Flu Vaccine
    1.4 Market Analysis by Application
        1.4.1 Overview: Global Live Attenuated Influenza Vaccine (LAIV) Consumption Value by Application: 2019 Versus 2023 Versus 2030
        1.4.2 Hospital
        1.4.3 Clinic
        1.4.4 Public Health Agency
        1.4.5 Other
    1.5 Global Live Attenuated Influenza Vaccine (LAIV) Market Size & Forecast
        1.5.1 Global Live Attenuated Influenza Vaccine (LAIV) Consumption Value (2019 & 2023 & 2030)
        1.5.2 Global Live Attenuated Influenza Vaccine (LAIV) Sales Quantity (2019-2030)
        1.5.3 Global Live Attenuated Influenza Vaccine (LAIV) Average Price (2019-2030)

2 Manufacturers Profiles
    2.1 Sanofi Pasteur
        2.1.1 Sanofi Pasteur Details
        2.1.2 Sanofi Pasteur Major Business
        2.1.3 Sanofi Pasteur Live Attenuated Influenza Vaccine (LAIV) Product and Services
        2.1.4 Sanofi Pasteur Live Attenuated Influenza Vaccine (LAIV) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
        2.1.5 Sanofi Pasteur Recent Developments/Updates
    2.2 AstraZeneca
        2.2.1 AstraZeneca Details
        2.2.2 AstraZeneca Major Business
        2.2.3 AstraZeneca Live Attenuated Influenza Vaccine (LAIV) Product and Services
        2.2.4 AstraZeneca Live Attenuated Influenza Vaccine (LAIV) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
        2.2.5 AstraZeneca Recent Developments/Updates
    2.3 CSL
        2.3.1 CSL Details
        2.3.2 CSL Major Business
        2.3.3 CSL Live Attenuated Influenza Vaccine (LAIV) Product and Services
        2.3.4 CSL Live Attenuated Influenza Vaccine (LAIV) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
        2.3.5 CSL Recent Developments/Updates
    2.4 Abbott
        2.4.1 Abbott Details
        2.4.2 Abbott Major Business
        2.4.3 Abbott Live Attenuated Influenza Vaccine (LAIV) Product and Services
        2.4.4 Abbott Live Attenuated Influenza Vaccine (LAIV) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
        2.4.5 Abbott Recent Developments/Updates
    2.5 GlaxoSmithKline
        2.5.1 GlaxoSmithKline Details
        2.5.2 GlaxoSmithKline Major Business
        2.5.3 GlaxoSmithKline Live Attenuated Influenza Vaccine (LAIV) Product and Services
        2.5.4 GlaxoSmithKline Live Attenuated Influenza Vaccine (LAIV) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
        2.5.5 GlaxoSmithKline Recent Developments/Updates
    2.6 Serum Institute
        2.6.1 Serum Institute Details
        2.6.2 Serum Institute Major Business
        2.6.3 Serum Institute Live Attenuated Influenza Vaccine (LAIV) Product and Services
        2.6.4 Serum Institute Live Attenuated Influenza Vaccine (LAIV) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
        2.6.5 Serum Institute Recent Developments/Updates
    2.7 Fluenz Tetra
        2.7.1 Fluenz Tetra Details
        2.7.2 Fluenz Tetra Major Business
        2.7.3 Fluenz Tetra Live Attenuated Influenza Vaccine (LAIV) Product and Services
        2.7.4 Fluenz Tetra Live Attenuated Influenza Vaccine (LAIV) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
        2.7.5 Fluenz Tetra Recent Developments/Updates
    2.8 Cytiva
        2.8.1 Cytiva Details
        2.8.2 Cytiva Major Business
        2.8.3 Cytiva Live Attenuated Influenza Vaccine (LAIV) Product and Services
        2.8.4 Cytiva Live Attenuated Influenza Vaccine (LAIV) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
        2.8.5 Cytiva Recent Developments/Updates
    2.9 BioDiem
        2.9.1 BioDiem Details
        2.9.2 BioDiem Major Business
        2.9.3 BioDiem Live Attenuated Influenza Vaccine (LAIV) Product and Services
        2.9.4 BioDiem Live Attenuated Influenza Vaccine (LAIV) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
        2.9.5 BioDiem Recent Developments/Updates
    2.10 FluMist
        2.10.1 FluMist Details
        2.10.2 FluMist Major Business
        2.10.3 FluMist Live Attenuated Influenza Vaccine (LAIV) Product and Services
        2.10.4 FluMist Live Attenuated Influenza Vaccine (LAIV) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
        2.10.5 FluMist Recent Developments/Updates
    2.11 GSK
        2.11.1 GSK Details
        2.11.2 GSK Major Business
        2.11.3 GSK Live Attenuated Influenza Vaccine (LAIV) Product and Services
        2.11.4 GSK Live Attenuated Influenza Vaccine (LAIV) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
        2.11.5 GSK Recent Developments/Updates
    2.12 ChangChun High & New Technology
        2.12.1 ChangChun High & New Technology Details
        2.12.2 ChangChun High & New Technology Major Business
        2.12.3 ChangChun High & New Technology Live Attenuated Influenza Vaccine (LAIV) Product and Services
        2.12.4 ChangChun High & New Technology Live Attenuated Influenza Vaccine (LAIV) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
        2.12.5 ChangChun High & New Technology Recent Developments/Updates
    2.13 BCHT Biotechnology
        2.13.1 BCHT Biotechnology Details
        2.13.2 BCHT Biotechnology Major Business
        2.13.3 BCHT Biotechnology Live Attenuated Influenza Vaccine (LAIV) Product and Services
        2.13.4 BCHT Biotechnology Live Attenuated Influenza Vaccine (LAIV) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
        2.13.5 BCHT Biotechnology Recent Developments/Updates

3 Competitive Environment: Live Attenuated Influenza Vaccine (LAIV) by Manufacturer
    3.1 Global Live Attenuated Influenza Vaccine (LAIV) Sales Quantity by Manufacturer (2019-2024)
    3.2 Global Live Attenuated Influenza Vaccine (LAIV) Revenue by Manufacturer (2019-2024)
    3.3 Global Live Attenuated Influenza Vaccine (LAIV) Average Price by Manufacturer (2019-2024)
    3.4 Market Share Analysis (2023)
        3.4.1 Producer Shipments of Live Attenuated Influenza Vaccine (LAIV) by Manufacturer Revenue ($MM) and Market Share (%): 2023
        3.4.2 Top 3 Live Attenuated Influenza Vaccine (LAIV) Manufacturer Market Share in 2023
        3.4.2 Top 6 Live Attenuated Influenza Vaccine (LAIV) Manufacturer Market Share in 2023
    3.5 Live Attenuated Influenza Vaccine (LAIV) Market: Overall Company Footprint Analysis
        3.5.1 Live Attenuated Influenza Vaccine (LAIV) Market: Region Footprint
        3.5.2 Live Attenuated Influenza Vaccine (LAIV) Market: Company Product Type Footprint
        3.5.3 Live Attenuated Influenza Vaccine (LAIV) Market: Company Product Application Footprint
    3.6 New Market Entrants and Barriers to Market Entry
    3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region
    4.1 Global Live Attenuated Influenza Vaccine (LAIV) Market Size by Region
        4.1.1 Global Live Attenuated Influenza Vaccine (LAIV) Sales Quantity by Region (2019-2030)
        4.1.2 Global Live Attenuated Influenza Vaccine (LAIV) Consumption Value by Region (2019-2030)
        4.1.3 Global Live Attenuated Influenza Vaccine (LAIV) Average Price by Region (2019-2030)
    4.2 North America Live Attenuated Influenza Vaccine (LAIV) Consumption Value (2019-2030)
    4.3 Europe Live Attenuated Influenza Vaccine (LAIV) Consumption Value (2019-2030)
    4.4 Asia-Pacific Live Attenuated Influenza Vaccine (LAIV) Consumption Value (2019-2030)
    4.5 South America Live Attenuated Influenza Vaccine (LAIV) Consumption Value (2019-2030)
    4.6 Middle East and Africa Live Attenuated Influenza Vaccine (LAIV) Consumption Value (2019-2030)

5 Market Segment by Type
    5.1 Global Live Attenuated Influenza Vaccine (LAIV) Sales Quantity by Type (2019-2030)
    5.2 Global Live Attenuated Influenza Vaccine (LAIV) Consumption Value by Type (2019-2030)
    5.3 Global Live Attenuated Influenza Vaccine (LAIV) Average Price by Type (2019-2030)

6 Market Segment by Application
    6.1 Global Live Attenuated Influenza Vaccine (LAIV) Sales Quantity by Application (2019-2030)
    6.2 Global Live Attenuated Influenza Vaccine (LAIV) Consumption Value by Application (2019-2030)
    6.3 Global Live Attenuated Influenza Vaccine (LAIV) Average Price by Application (2019-2030)

7 North America
    7.1 North America Live Attenuated Influenza Vaccine (LAIV) Sales Quantity by Type (2019-2030)
    7.2 North America Live Attenuated Influenza Vaccine (LAIV) Sales Quantity by Application (2019-2030)
    7.3 North America Live Attenuated Influenza Vaccine (LAIV) Market Size by Country
        7.3.1 North America Live Attenuated Influenza Vaccine (LAIV) Sales Quantity by Country (2019-2030)
        7.3.2 North America Live Attenuated Influenza Vaccine (LAIV) Consumption Value by Country (2019-2030)
        7.3.3 United States Market Size and Forecast (2019-2030)
        7.3.4 Canada Market Size and Forecast (2019-2030)
        7.3.5 Mexico Market Size and Forecast (2019-2030)

8 Europe
    8.1 Europe Live Attenuated Influenza Vaccine (LAIV) Sales Quantity by Type (2019-2030)
    8.2 Europe Live Attenuated Influenza Vaccine (LAIV) Sales Quantity by Application (2019-2030)
    8.3 Europe Live Attenuated Influenza Vaccine (LAIV) Market Size by Country
        8.3.1 Europe Live Attenuated Influenza Vaccine (LAIV) Sales Quantity by Country (2019-2030)
        8.3.2 Europe Live Attenuated Influenza Vaccine (LAIV) Consumption Value by Country (2019-2030)
        8.3.3 Germany Market Size and Forecast (2019-2030)
        8.3.4 France Market Size and Forecast (2019-2030)
        8.3.5 United Kingdom Market Size and Forecast (2019-2030)
        8.3.6 Russia Market Size and Forecast (2019-2030)
        8.3.7 Italy Market Size and Forecast (2019-2030)

9 Asia-Pacific
    9.1 Asia-Pacific Live Attenuated Influenza Vaccine (LAIV) Sales Quantity by Type (2019-2030)
    9.2 Asia-Pacific Live Attenuated Influenza Vaccine (LAIV) Sales Quantity by Application (2019-2030)
    9.3 Asia-Pacific Live Attenuated Influenza Vaccine (LAIV) Market Size by Region
        9.3.1 Asia-Pacific Live Attenuated Influenza Vaccine (LAIV) Sales Quantity by Region (2019-2030)
        9.3.2 Asia-Pacific Live Attenuated Influenza Vaccine (LAIV) Consumption Value by Region (2019-2030)
        9.3.3 China Market Size and Forecast (2019-2030)
        9.3.4 Japan Market Size and Forecast (2019-2030)
        9.3.5 Korea Market Size and Forecast (2019-2030)
        9.3.6 India Market Size and Forecast (2019-2030)
        9.3.7 Southeast Asia Market Size and Forecast (2019-2030)
        9.3.8 Australia Market Size and Forecast (2019-2030)

10 South America
    10.1 South America Live Attenuated Influenza Vaccine (LAIV) Sales Quantity by Type (2019-2030)
    10.2 South America Live Attenuated Influenza Vaccine (LAIV) Sales Quantity by Application (2019-2030)
    10.3 South America Live Attenuated Influenza Vaccine (LAIV) Market Size by Country
        10.3.1 South America Live Attenuated Influenza Vaccine (LAIV) Sales Quantity by Country (2019-2030)
        10.3.2 South America Live Attenuated Influenza Vaccine (LAIV) Consumption Value by Country (2019-2030)
        10.3.3 Brazil Market Size and Forecast (2019-2030)
        10.3.4 Argentina Market Size and Forecast (2019-2030)

11 Middle East & Africa
    11.1 Middle East & Africa Live Attenuated Influenza Vaccine (LAIV) Sales Quantity by Type (2019-2030)
    11.2 Middle East & Africa Live Attenuated Influenza Vaccine (LAIV) Sales Quantity by Application (2019-2030)
    11.3 Middle East & Africa Live Attenuated Influenza Vaccine (LAIV) Market Size by Country
        11.3.1 Middle East & Africa Live Attenuated Influenza Vaccine (LAIV) Sales Quantity by Country (2019-2030)
        11.3.2 Middle East & Africa Live Attenuated Influenza Vaccine (LAIV) Consumption Value by Country (2019-2030)
        11.3.3 Turkey Market Size and Forecast (2019-2030)
        11.3.4 Egypt Market Size and Forecast (2019-2030)
        11.3.5 Saudi Arabia Market Size and Forecast (2019-2030)
        11.3.6 South Africa Market Size and Forecast (2019-2030)

12 Market Dynamics
    12.1 Live Attenuated Influenza Vaccine (LAIV) Market Drivers
    12.2 Live Attenuated Influenza Vaccine (LAIV) Market Restraints
    12.3 Live Attenuated Influenza Vaccine (LAIV) Trends Analysis
    12.4 Porters Five Forces Analysis
        12.4.1 Threat of New Entrants
        12.4.2 Bargaining Power of Suppliers
        12.4.3 Bargaining Power of Buyers
        12.4.4 Threat of Substitutes
        12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain
    13.1 Raw Material of Live Attenuated Influenza Vaccine (LAIV) and Key Manufacturers
    13.2 Manufacturing Costs Percentage of Live Attenuated Influenza Vaccine (LAIV)
    13.3 Live Attenuated Influenza Vaccine (LAIV) Production Process
    13.4 Live Attenuated Influenza Vaccine (LAIV) Industrial Chain

14 Shipments by Distribution Channel
    14.1 Sales Channel
        14.1.1 Direct to End-User
        14.1.2 Distributors
    14.2 Live Attenuated Influenza Vaccine (LAIV) Typical Distributors
    14.3 Live Attenuated Influenza Vaccine (LAIV) Typical Customers

15 Research Findings and Conclusion

16 Appendix
    16.1 Methodology
    16.2 Research Process and Data Source
    16.3 Disclaimer

Table of Figures

List of Tables
    Table 1. Global Live Attenuated Influenza Vaccine (LAIV) Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
    Table 2. Global Live Attenuated Influenza Vaccine (LAIV) Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
    Table 3. Sanofi Pasteur Basic Information, Manufacturing Base and Competitors
    Table 4. Sanofi Pasteur Major Business
    Table 5. Sanofi Pasteur Live Attenuated Influenza Vaccine (LAIV) Product and Services
    Table 6. Sanofi Pasteur Live Attenuated Influenza Vaccine (LAIV) Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 7. Sanofi Pasteur Recent Developments/Updates
    Table 8. AstraZeneca Basic Information, Manufacturing Base and Competitors
    Table 9. AstraZeneca Major Business
    Table 10. AstraZeneca Live Attenuated Influenza Vaccine (LAIV) Product and Services
    Table 11. AstraZeneca Live Attenuated Influenza Vaccine (LAIV) Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 12. AstraZeneca Recent Developments/Updates
    Table 13. CSL Basic Information, Manufacturing Base and Competitors
    Table 14. CSL Major Business
    Table 15. CSL Live Attenuated Influenza Vaccine (LAIV) Product and Services
    Table 16. CSL Live Attenuated Influenza Vaccine (LAIV) Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 17. CSL Recent Developments/Updates
    Table 18. Abbott Basic Information, Manufacturing Base and Competitors
    Table 19. Abbott Major Business
    Table 20. Abbott Live Attenuated Influenza Vaccine (LAIV) Product and Services
    Table 21. Abbott Live Attenuated Influenza Vaccine (LAIV) Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 22. Abbott Recent Developments/Updates
    Table 23. GlaxoSmithKline Basic Information, Manufacturing Base and Competitors
    Table 24. GlaxoSmithKline Major Business
    Table 25. GlaxoSmithKline Live Attenuated Influenza Vaccine (LAIV) Product and Services
    Table 26. GlaxoSmithKline Live Attenuated Influenza Vaccine (LAIV) Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 27. GlaxoSmithKline Recent Developments/Updates
    Table 28. Serum Institute Basic Information, Manufacturing Base and Competitors
    Table 29. Serum Institute Major Business
    Table 30. Serum Institute Live Attenuated Influenza Vaccine (LAIV) Product and Services
    Table 31. Serum Institute Live Attenuated Influenza Vaccine (LAIV) Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 32. Serum Institute Recent Developments/Updates
    Table 33. Fluenz Tetra Basic Information, Manufacturing Base and Competitors
    Table 34. Fluenz Tetra Major Business
    Table 35. Fluenz Tetra Live Attenuated Influenza Vaccine (LAIV) Product and Services
    Table 36. Fluenz Tetra Live Attenuated Influenza Vaccine (LAIV) Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 37. Fluenz Tetra Recent Developments/Updates
    Table 38. Cytiva Basic Information, Manufacturing Base and Competitors
    Table 39. Cytiva Major Business
    Table 40. Cytiva Live Attenuated Influenza Vaccine (LAIV) Product and Services
    Table 41. Cytiva Live Attenuated Influenza Vaccine (LAIV) Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 42. Cytiva Recent Developments/Updates
    Table 43. BioDiem Basic Information, Manufacturing Base and Competitors
    Table 44. BioDiem Major Business
    Table 45. BioDiem Live Attenuated Influenza Vaccine (LAIV) Product and Services
    Table 46. BioDiem Live Attenuated Influenza Vaccine (LAIV) Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 47. BioDiem Recent Developments/Updates
    Table 48. FluMist Basic Information, Manufacturing Base and Competitors
    Table 49. FluMist Major Business
    Table 50. FluMist Live Attenuated Influenza Vaccine (LAIV) Product and Services
    Table 51. FluMist Live Attenuated Influenza Vaccine (LAIV) Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 52. FluMist Recent Developments/Updates
    Table 53. GSK Basic Information, Manufacturing Base and Competitors
    Table 54. GSK Major Business
    Table 55. GSK Live Attenuated Influenza Vaccine (LAIV) Product and Services
    Table 56. GSK Live Attenuated Influenza Vaccine (LAIV) Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 57. GSK Recent Developments/Updates
    Table 58. ChangChun High & New Technology Basic Information, Manufacturing Base and Competitors
    Table 59. ChangChun High & New Technology Major Business
    Table 60. ChangChun High & New Technology Live Attenuated Influenza Vaccine (LAIV) Product and Services
    Table 61. ChangChun High & New Technology Live Attenuated Influenza Vaccine (LAIV) Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 62. ChangChun High & New Technology Recent Developments/Updates
    Table 63. BCHT Biotechnology Basic Information, Manufacturing Base and Competitors
    Table 64. BCHT Biotechnology Major Business
    Table 65. BCHT Biotechnology Live Attenuated Influenza Vaccine (LAIV) Product and Services
    Table 66. BCHT Biotechnology Live Attenuated Influenza Vaccine (LAIV) Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 67. BCHT Biotechnology Recent Developments/Updates
    Table 68. Global Live Attenuated Influenza Vaccine (LAIV) Sales Quantity by Manufacturer (2019-2024) & (K Units)
    Table 69. Global Live Attenuated Influenza Vaccine (LAIV) Revenue by Manufacturer (2019-2024) & (USD Million)
    Table 70. Global Live Attenuated Influenza Vaccine (LAIV) Average Price by Manufacturer (2019-2024) & (US$/Unit)
    Table 71. Market Position of Manufacturers in Live Attenuated Influenza Vaccine (LAIV), (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2023
    Table 72. Head Office and Live Attenuated Influenza Vaccine (LAIV) Production Site of Key Manufacturer
    Table 73. Live Attenuated Influenza Vaccine (LAIV) Market: Company Product Type Footprint
    Table 74. Live Attenuated Influenza Vaccine (LAIV) Market: Company Product Application Footprint
    Table 75. Live Attenuated Influenza Vaccine (LAIV) New Market Entrants and Barriers to Market Entry
    Table 76. Live Attenuated Influenza Vaccine (LAIV) Mergers, Acquisition, Agreements, and Collaborations
    Table 77. Global Live Attenuated Influenza Vaccine (LAIV) Sales Quantity by Region (2019-2024) & (K Units)
    Table 78. Global Live Attenuated Influenza Vaccine (LAIV) Sales Quantity by Region (2025-2030) & (K Units)
    Table 79. Global Live Attenuated Influenza Vaccine (LAIV) Consumption Value by Region (2019-2024) & (USD Million)
    Table 80. Global Live Attenuated Influenza Vaccine (LAIV) Consumption Value by Region (2025-2030) & (USD Million)
    Table 81. Global Live Attenuated Influenza Vaccine (LAIV) Average Price by Region (2019-2024) & (US$/Unit)
    Table 82. Global Live Attenuated Influenza Vaccine (LAIV) Average Price by Region (2025-2030) & (US$/Unit)
    Table 83. Global Live Attenuated Influenza Vaccine (LAIV) Sales Quantity by Type (2019-2024) & (K Units)
    Table 84. Global Live Attenuated Influenza Vaccine (LAIV) Sales Quantity by Type (2025-2030) & (K Units)
    Table 85. Global Live Attenuated Influenza Vaccine (LAIV) Consumption Value by Type (2019-2024) & (USD Million)
    Table 86. Global Live Attenuated Influenza Vaccine (LAIV) Consumption Value by Type (2025-2030) & (USD Million)
    Table 87. Global Live Attenuated Influenza Vaccine (LAIV) Average Price by Type (2019-2024) & (US$/Unit)
    Table 88. Global Live Attenuated Influenza Vaccine (LAIV) Average Price by Type (2025-2030) & (US$/Unit)
    Table 89. Global Live Attenuated Influenza Vaccine (LAIV) Sales Quantity by Application (2019-2024) & (K Units)
    Table 90. Global Live Attenuated Influenza Vaccine (LAIV) Sales Quantity by Application (2025-2030) & (K Units)
    Table 91. Global Live Attenuated Influenza Vaccine (LAIV) Consumption Value by Application (2019-2024) & (USD Million)
    Table 92. Global Live Attenuated Influenza Vaccine (LAIV) Consumption Value by Application (2025-2030) & (USD Million)
    Table 93. Global Live Attenuated Influenza Vaccine (LAIV) Average Price by Application (2019-2024) & (US$/Unit)
    Table 94. Global Live Attenuated Influenza Vaccine (LAIV) Average Price by Application (2025-2030) & (US$/Unit)
    Table 95. North America Live Attenuated Influenza Vaccine (LAIV) Sales Quantity by Type (2019-2024) & (K Units)
    Table 96. North America Live Attenuated Influenza Vaccine (LAIV) Sales Quantity by Type (2025-2030) & (K Units)
    Table 97. North America Live Attenuated Influenza Vaccine (LAIV) Sales Quantity by Application (2019-2024) & (K Units)
    Table 98. North America Live Attenuated Influenza Vaccine (LAIV) Sales Quantity by Application (2025-2030) & (K Units)
    Table 99. North America Live Attenuated Influenza Vaccine (LAIV) Sales Quantity by Country (2019-2024) & (K Units)
    Table 100. North America Live Attenuated Influenza Vaccine (LAIV) Sales Quantity by Country (2025-2030) & (K Units)
    Table 101. North America Live Attenuated Influenza Vaccine (LAIV) Consumption Value by Country (2019-2024) & (USD Million)
    Table 102. North America Live Attenuated Influenza Vaccine (LAIV) Consumption Value by Country (2025-2030) & (USD Million)
    Table 103. Europe Live Attenuated Influenza Vaccine (LAIV) Sales Quantity by Type (2019-2024) & (K Units)
    Table 104. Europe Live Attenuated Influenza Vaccine (LAIV) Sales Quantity by Type (2025-2030) & (K Units)
    Table 105. Europe Live Attenuated Influenza Vaccine (LAIV) Sales Quantity by Application (2019-2024) & (K Units)
    Table 106. Europe Live Attenuated Influenza Vaccine (LAIV) Sales Quantity by Application (2025-2030) & (K Units)
    Table 107. Europe Live Attenuated Influenza Vaccine (LAIV) Sales Quantity by Country (2019-2024) & (K Units)
    Table 108. Europe Live Attenuated Influenza Vaccine (LAIV) Sales Quantity by Country (2025-2030) & (K Units)
    Table 109. Europe Live Attenuated Influenza Vaccine (LAIV) Consumption Value by Country (2019-2024) & (USD Million)
    Table 110. Europe Live Attenuated Influenza Vaccine (LAIV) Consumption Value by Country (2025-2030) & (USD Million)
    Table 111. Asia-Pacific Live Attenuated Influenza Vaccine (LAIV) Sales Quantity by Type (2019-2024) & (K Units)
    Table 112. Asia-Pacific Live Attenuated Influenza Vaccine (LAIV) Sales Quantity by Type (2025-2030) & (K Units)
    Table 113. Asia-Pacific Live Attenuated Influenza Vaccine (LAIV) Sales Quantity by Application (2019-2024) & (K Units)
    Table 114. Asia-Pacific Live Attenuated Influenza Vaccine (LAIV) Sales Quantity by Application (2025-2030) & (K Units)
    Table 115. Asia-Pacific Live Attenuated Influenza Vaccine (LAIV) Sales Quantity by Region (2019-2024) & (K Units)
    Table 116. Asia-Pacific Live Attenuated Influenza Vaccine (LAIV) Sales Quantity by Region (2025-2030) & (K Units)
    Table 117. Asia-Pacific Live Attenuated Influenza Vaccine (LAIV) Consumption Value by Region (2019-2024) & (USD Million)
    Table 118. Asia-Pacific Live Attenuated Influenza Vaccine (LAIV) Consumption Value by Region (2025-2030) & (USD Million)
    Table 119. South America Live Attenuated Influenza Vaccine (LAIV) Sales Quantity by Type (2019-2024) & (K Units)
    Table 120. South America Live Attenuated Influenza Vaccine (LAIV) Sales Quantity by Type (2025-2030) & (K Units)
    Table 121. South America Live Attenuated Influenza Vaccine (LAIV) Sales Quantity by Application (2019-2024) & (K Units)
    Table 122. South America Live Attenuated Influenza Vaccine (LAIV) Sales Quantity by Application (2025-2030) & (K Units)
    Table 123. South America Live Attenuated Influenza Vaccine (LAIV) Sales Quantity by Country (2019-2024) & (K Units)
    Table 124. South America Live Attenuated Influenza Vaccine (LAIV) Sales Quantity by Country (2025-2030) & (K Units)
    Table 125. South America Live Attenuated Influenza Vaccine (LAIV) Consumption Value by Country (2019-2024) & (USD Million)
    Table 126. South America Live Attenuated Influenza Vaccine (LAIV) Consumption Value by Country (2025-2030) & (USD Million)
    Table 127. Middle East & Africa Live Attenuated Influenza Vaccine (LAIV) Sales Quantity by Type (2019-2024) & (K Units)
    Table 128. Middle East & Africa Live Attenuated Influenza Vaccine (LAIV) Sales Quantity by Type (2025-2030) & (K Units)
    Table 129. Middle East & Africa Live Attenuated Influenza Vaccine (LAIV) Sales Quantity by Application (2019-2024) & (K Units)
    Table 130. Middle East & Africa Live Attenuated Influenza Vaccine (LAIV) Sales Quantity by Application (2025-2030) & (K Units)
    Table 131. Middle East & Africa Live Attenuated Influenza Vaccine (LAIV) Sales Quantity by Region (2019-2024) & (K Units)
    Table 132. Middle East & Africa Live Attenuated Influenza Vaccine (LAIV) Sales Quantity by Region (2025-2030) & (K Units)
    Table 133. Middle East & Africa Live Attenuated Influenza Vaccine (LAIV) Consumption Value by Region (2019-2024) & (USD Million)
    Table 134. Middle East & Africa Live Attenuated Influenza Vaccine (LAIV) Consumption Value by Region (2025-2030) & (USD Million)
    Table 135. Live Attenuated Influenza Vaccine (LAIV) Raw Material
    Table 136. Key Manufacturers of Live Attenuated Influenza Vaccine (LAIV) Raw Materials
    Table 137. Live Attenuated Influenza Vaccine (LAIV) Typical Distributors
    Table 138. Live Attenuated Influenza Vaccine (LAIV) Typical Customers
List of Figures
    Figure 1. Live Attenuated Influenza Vaccine (LAIV) Picture
    Figure 2. Global Live Attenuated Influenza Vaccine (LAIV) Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
    Figure 3. Global Live Attenuated Influenza Vaccine (LAIV) Consumption Value Market Share by Type in 2023
    Figure 4. Trivalent Flu Vaccine Examples
    Figure 5. Quadrivalent Flu Vaccine Examples
    Figure 6. Global Live Attenuated Influenza Vaccine (LAIV) Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
    Figure 7. Global Live Attenuated Influenza Vaccine (LAIV) Consumption Value Market Share by Application in 2023
    Figure 8. Hospital Examples
    Figure 9. Clinic Examples
    Figure 10. Public Health Agency Examples
    Figure 11. Other Examples
    Figure 12. Global Live Attenuated Influenza Vaccine (LAIV) Consumption Value, (USD Million): 2019 & 2023 & 2030
    Figure 13. Global Live Attenuated Influenza Vaccine (LAIV) Consumption Value and Forecast (2019-2030) & (USD Million)
    Figure 14. Global Live Attenuated Influenza Vaccine (LAIV) Sales Quantity (2019-2030) & (K Units)
    Figure 15. Global Live Attenuated Influenza Vaccine (LAIV) Average Price (2019-2030) & (US$/Unit)
    Figure 16. Global Live Attenuated Influenza Vaccine (LAIV) Sales Quantity Market Share by Manufacturer in 2023
    Figure 17. Global Live Attenuated Influenza Vaccine (LAIV) Consumption Value Market Share by Manufacturer in 2023
    Figure 18. Producer Shipments of Live Attenuated Influenza Vaccine (LAIV) by Manufacturer Sales Quantity ($MM) and Market Share (%): 2023
    Figure 19. Top 3 Live Attenuated Influenza Vaccine (LAIV) Manufacturer (Consumption Value) Market Share in 2023
    Figure 20. Top 6 Live Attenuated Influenza Vaccine (LAIV) Manufacturer (Consumption Value) Market Share in 2023
    Figure 21. Global Live Attenuated Influenza Vaccine (LAIV) Sales Quantity Market Share by Region (2019-2030)
    Figure 22. Global Live Attenuated Influenza Vaccine (LAIV) Consumption Value Market Share by Region (2019-2030)
    Figure 23. North America Live Attenuated Influenza Vaccine (LAIV) Consumption Value (2019-2030) & (USD Million)
    Figure 24. Europe Live Attenuated Influenza Vaccine (LAIV) Consumption Value (2019-2030) & (USD Million)
    Figure 25. Asia-Pacific Live Attenuated Influenza Vaccine (LAIV) Consumption Value (2019-2030) & (USD Million)
    Figure 26. South America Live Attenuated Influenza Vaccine (LAIV) Consumption Value (2019-2030) & (USD Million)
    Figure 27. Middle East & Africa Live Attenuated Influenza Vaccine (LAIV) Consumption Value (2019-2030) & (USD Million)
    Figure 28. Global Live Attenuated Influenza Vaccine (LAIV) Sales Quantity Market Share by Type (2019-2030)
    Figure 29. Global Live Attenuated Influenza Vaccine (LAIV) Consumption Value Market Share by Type (2019-2030)
    Figure 30. Global Live Attenuated Influenza Vaccine (LAIV) Average Price by Type (2019-2030) & (US$/Unit)
    Figure 31. Global Live Attenuated Influenza Vaccine (LAIV) Sales Quantity Market Share by Application (2019-2030)
    Figure 32. Global Live Attenuated Influenza Vaccine (LAIV) Consumption Value Market Share by Application (2019-2030)
    Figure 33. Global Live Attenuated Influenza Vaccine (LAIV) Average Price by Application (2019-2030) & (US$/Unit)
    Figure 34. North America Live Attenuated Influenza Vaccine (LAIV) Sales Quantity Market Share by Type (2019-2030)
    Figure 35. North America Live Attenuated Influenza Vaccine (LAIV) Sales Quantity Market Share by Application (2019-2030)
    Figure 36. North America Live Attenuated Influenza Vaccine (LAIV) Sales Quantity Market Share by Country (2019-2030)
    Figure 37. North America Live Attenuated Influenza Vaccine (LAIV) Consumption Value Market Share by Country (2019-2030)
    Figure 38. United States Live Attenuated Influenza Vaccine (LAIV) Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 39. Canada Live Attenuated Influenza Vaccine (LAIV) Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 40. Mexico Live Attenuated Influenza Vaccine (LAIV) Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 41. Europe Live Attenuated Influenza Vaccine (LAIV) Sales Quantity Market Share by Type (2019-2030)
    Figure 42. Europe Live Attenuated Influenza Vaccine (LAIV) Sales Quantity Market Share by Application (2019-2030)
    Figure 43. Europe Live Attenuated Influenza Vaccine (LAIV) Sales Quantity Market Share by Country (2019-2030)
    Figure 44. Europe Live Attenuated Influenza Vaccine (LAIV) Consumption Value Market Share by Country (2019-2030)
    Figure 45. Germany Live Attenuated Influenza Vaccine (LAIV) Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 46. France Live Attenuated Influenza Vaccine (LAIV) Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 47. United Kingdom Live Attenuated Influenza Vaccine (LAIV) Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 48. Russia Live Attenuated Influenza Vaccine (LAIV) Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 49. Italy Live Attenuated Influenza Vaccine (LAIV) Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 50. Asia-Pacific Live Attenuated Influenza Vaccine (LAIV) Sales Quantity Market Share by Type (2019-2030)
    Figure 51. Asia-Pacific Live Attenuated Influenza Vaccine (LAIV) Sales Quantity Market Share by Application (2019-2030)
    Figure 52. Asia-Pacific Live Attenuated Influenza Vaccine (LAIV) Sales Quantity Market Share by Region (2019-2030)
    Figure 53. Asia-Pacific Live Attenuated Influenza Vaccine (LAIV) Consumption Value Market Share by Region (2019-2030)
    Figure 54. China Live Attenuated Influenza Vaccine (LAIV) Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 55. Japan Live Attenuated Influenza Vaccine (LAIV) Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 56. Korea Live Attenuated Influenza Vaccine (LAIV) Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 57. India Live Attenuated Influenza Vaccine (LAIV) Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 58. Southeast Asia Live Attenuated Influenza Vaccine (LAIV) Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 59. Australia Live Attenuated Influenza Vaccine (LAIV) Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 60. South America Live Attenuated Influenza Vaccine (LAIV) Sales Quantity Market Share by Type (2019-2030)
    Figure 61. South America Live Attenuated Influenza Vaccine (LAIV) Sales Quantity Market Share by Application (2019-2030)
    Figure 62. South America Live Attenuated Influenza Vaccine (LAIV) Sales Quantity Market Share by Country (2019-2030)
    Figure 63. South America Live Attenuated Influenza Vaccine (LAIV) Consumption Value Market Share by Country (2019-2030)
    Figure 64. Brazil Live Attenuated Influenza Vaccine (LAIV) Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 65. Argentina Live Attenuated Influenza Vaccine (LAIV) Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 66. Middle East & Africa Live Attenuated Influenza Vaccine (LAIV) Sales Quantity Market Share by Type (2019-2030)
    Figure 67. Middle East & Africa Live Attenuated Influenza Vaccine (LAIV) Sales Quantity Market Share by Application (2019-2030)
    Figure 68. Middle East & Africa Live Attenuated Influenza Vaccine (LAIV) Sales Quantity Market Share by Region (2019-2030)
    Figure 69. Middle East & Africa Live Attenuated Influenza Vaccine (LAIV) Consumption Value Market Share by Region (2019-2030)
    Figure 70. Turkey Live Attenuated Influenza Vaccine (LAIV) Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 71. Egypt Live Attenuated Influenza Vaccine (LAIV) Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 72. Saudi Arabia Live Attenuated Influenza Vaccine (LAIV) Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 73. South Africa Live Attenuated Influenza Vaccine (LAIV) Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 74. Live Attenuated Influenza Vaccine (LAIV) Market Drivers
    Figure 75. Live Attenuated Influenza Vaccine (LAIV) Market Restraints
    Figure 76. Live Attenuated Influenza Vaccine (LAIV) Market Trends
    Figure 77. Porters Five Forces Analysis
    Figure 78. Manufacturing Cost Structure Analysis of Live Attenuated Influenza Vaccine (LAIV) in 2023
    Figure 79. Manufacturing Process Analysis of Live Attenuated Influenza Vaccine (LAIV)
    Figure 80. Live Attenuated Influenza Vaccine (LAIV) Industrial Chain
    Figure 81. Sales Quantity Channel: Direct to End-User vs Distributors
    Figure 82. Direct Channel Pros & Cons
    Figure 83. Indirect Channel Pros & Cons
    Figure 84. Methodology
    Figure 85. Research Process and Data Source

Research Methodology

Client Requirements

Review and analyze client requirements

Discussion of all the project requirements and queries

Flexibility Check

Project Feasibility Analysis

Finalizing tentative research programme

Structuring project proposal with scope, timeline, and costs

Analyzing Market Dynamics

Determination of key drivers, restraints, challenge, and opportunity

Identifies market needs and trends

Market Size Estimation & Forecast

Estimation of historical data based on secondary and primary data

Anticipating market recast by assigning weightage to market forces (drivers, restraints, opportunities)

Freezing historical and forecast market size estimations based on evolution, trends, outlook, and strategies

Consideration of geography, region-specific product/service demand for region segments

Consideration of product utilization rates, product demand outlook for segments by application or end-user.

Data Source

Secondary Source
Data collections from annual reports, presentations,associations, journals, analyst reports, paid database, press releases, blogs, newsletters,and GIR repositories.

Primary Source
Research discussion with manufacturers, distributors, suppliers, end user, industry experts to verify insights.

Validation and
triangulation of
secondary and primary source.

Collection of data

Cumulating and collating the essential qualitative and quantitative data

Generation of report in client requested format by research analysts

Reviews by expert analysts

Final quality check

Clarifying queries

Receiving feedback

Ensuring satisfaction

01 Identification of data

This step involves identification of several primary and secondary data research sources, including Global Info Research's internal data sources. The primary sources consist of in-depth discussions and interviews with policy makers, industry experts, and data evaluators, whereas secondary sources include a thorough study of market journals, press releases, annual reports, and government and non-government agencies websites.
02 Evaluation of Market Dynamic

This phase includes a detailed evaluation of several factors that are likely to affect the market dynamics. It involves a comprehensive assessment of major market pain points, drivers, and trends. It also comprises a detailed study of research plans and methodology.
03 Collection of Data

This process consists of gathering data, accessing proprietary databases, and reaching out to key industry participants that operate in the market across the value chain. It also involves studying several patterns in the historical data and comparing it with the current scenario.
04 Collaboration of Data

This stage involves the validation of data and arrival at actual statistics, and evolution of the market over the years. It entails the study and analyzes various segments and verticals of the market. An impact analysis is also performed to observe which factors will affect the market in the next few years.
05 Verification and Analysis

This is the final stage, which involves both quantity and quality checks. Although the process of data verification is an integral part of the research process, all data points and statistics and figures are re-checked to uphold their authenticity and validity.

Companies Mentioned

Sanofi Pasteur
AstraZeneca
CSL
Abbott
GlaxoSmithKline
Serum Institute
Fluenz Tetra
Cytiva
BioDiem
FluMist
GSK
ChangChun High & New Technology
BCHT Biotechnology

Related Reports

Global Live Attenuated Influenza Vaccine (LAIV) Supply, Demand and Key Producers, 2023-2029

Global Live Attenuated Influenza Vaccine (LAIV) Supply, Demand and Key Producers, 2023-2029

date 19 Feb 2023

date Pharma & Healthcare

The global Live Attenuated Influenza Vaccine (LAIV) market size is expected to reach $ million by 2029, rising at a market growth of % CAGR during the forecast period (2023-2029).

Product Tags

Live Attenuated Influenza Vaccine (LAIV)

GABA Supplements

L-carnitine Capsule

Opical Thrombin

Purchase Options

Single User License

USD3480.00

Multi User License

USD5220.00

Corporate Users License

USD6960.00

Add To Cart

Buy Now

Popular Product Keywords

AI
semiconductor
electron
5G
artificial intelligence
Battery
new energy
We Provide Professional, Accurate Market Analysis to Help You Stay Ahead of Your Competition.

Speak to our analyst >>
Our Clients
What We Can Provide?

With better results and higher quality products,Our professional reports can achieve four things:
- Insight into the industry market information
- Analyze market development needs
- Prospects for future development
- Develop industry investment strategy
Digging deeper into global industry information and providing market strategies.

Contact Us >>